Medically Reviewed By:
Written By:
Last Modified April 17, 2022
This page features 15 Cited Research Articles
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating
Read Our Testimonials
Jump To A Topic

What is Bevacizumab?

In early clinical trials, bevacizumab (Avastin) helped some mesothelioma patients live longer when combined with chemotherapy drugs cisplatin and pemetrexed (Alimta).

Bevacizumab improved survival time by 2.7 months in a 2016 phase III clinical trial in France. Patients taking a combination of the three drugs survived an average of 18.8 months, compared to 16.1 months for patients only receiving cisplatin and pemetrexed.

In a 2021 research study, 61% of mesothelioma patients prescribed a combination of atezolizumab with bevacizumab had no progression of disease after one year, and overall survival at one year was 85%.

However, bevacizumab’s rare but serious side effects have some researchers questioning its safety. The phase III clinical trial showed that although the side effects were significantly higher for patients taking bevacizumab, they were deemed mostly manageable.

How Does Bevacizumab Work?

Doctors may inject the drug or give it through an intravenous drip, a process that can take a few hours. Patients generally need the drug once every three weeks.

Bevacizumab is sometimes classified as a chemotherapy drug, but it does not fight cancer in the usual way as a cytotoxic agent attacks the disease. Whereas typical chemotherapy attacks rapidly dividing cancer cells, this drug ensures that tumors don’t receive necessities like oxygen and nutrients.

It does this by inhibiting angiogenesis, which is the growth of blood vessels within the tumor. If angiogenesis occurs, mesothelioma cells have a support system within the body and can divide and spread more easily.

But without angiogenesis, cancer cells are starved of vital nutrients and slowly die. When bevacizumab prevents angiogenesis, it stops mesothelioma from spreading and kills cancer cells that are already present.

Bevacizumab Information
Name Avastin
Alternate Names Bevacizumab
Manufacturer Roche/Genetech
Dosage 15 mg/kg every three weeks
Administration Route Intravenous
Active Ingredient Bevacizumab
Drug Class Anti-angiogenic agent
Medical Code J9035, C9257
Related Drug Bevacizumab-awwb (Mvasi)
Interacting Drug Quadramet, deferiphrone, pantiumumab, sunitinib, thalidomide
Medical Studies Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
FDA Warning Gastrointestinal perforation or fistula, arterial thromboembolic events, hypertension, proteinuria, ovarian failure, infusion reactions, posterior reversible encephalopathy syndrome
Find a Mesothelioma Cancer Center
Access top mesothelioma cancer centers that have experience treating this rare disease.

In some cancers, including mesothelioma, it is commonly used in combination with other chemotherapy drugs such as a cisplatin-based chemotherapy regimen. Some clinicians have also combined bevacizumab with a second-line chemotherapeutic agent called gemcitabine.

When used in this combined treatment fashion, bevacizumab works to stop angiogenesis while other drugs have a direct cytotoxic effect on the tumor cells.

However, as it is with many multiagent anticancer protocols, oncologist had expressed concern that some treatment combinations with bevacizumab may place some mesothelioma patients at an increased risk of experiencing untoward side effects.

Side Effects of Bevacizumab

Bevacizumab commonly causes minor side effects such as dizziness, dry mouth, fatigue, heartburn and loss of appetite. In rare cases, it may cause severe side effects such as blood clots in the lungs, hemorrhaging, holes in the stomach and low white blood cell count. These potentially deadly complications are most common when it is used in conjunction with a chemotherapy drug.

A study of clinical trial results revealed that patients treated with bevacizumab and chemotherapy are 1.5 times more likely to die because of treatment complications than patients treated with chemotherapy alone.

Results of Bevacizumab Studies

A 2008 study tested the effects of bevacizumab with chemotherapy in 24 mesothelioma patients who previously underwent other treatments with no positive results.

The combination was successful in slowing disease progression in half of patients. Overall, patients lived a median of 5.8 months after being treated with the drug. Researchers reported that it was well-tolerated and warranted further study.

In a case study the following year, a mesothelioma patient underwent treatment with bevacizumab and gemcitabine after other treatments had failed to shrink his tumor or control his symptoms. The combination helped prevent fluid buildup and pain, leading to a better quality of life.

This finding suggests that bevacizumab may aid in palliative, symptom-reducing care in addition to potentially curative, life-extending treatment.


Mesothelioma packet from the Mesothelioma Center
Get Your Free Mesothelioma Treatment Guide
Healthy fish, vegetables and fruit
Watch Our Free Mesothelioma Nutrition Webinar
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?